Featured Research

from universities, journals, and other organizations

Divide and conquer strategy for childhood brain cancer

Date:
November 23, 2010
Source:
Children's Hospital Boston
Summary:
Medulloblastomas are the most common malignant brain tumors of childhood, with 40 to 50 percent overall mortality. One of the greatest challenges in treating them is that they vary substantially from patient to patient. In the largest genomic study of human medulloblastomas to date, researchers have identified six subtypes with distinct molecular "fingerprints" that will improve doctors' ability to direct and individualize treatment.

Medulloblastomas are the most common malignant brain tumors of childhood, with 40 to 50 percent overall mortality. One of the greatest challenges in treating them is that they vary substantially from patient to patient. In the largest genomic study of human medulloblastomas to date, researchers from Children's Hospital Boston, together with collaborators, have identified six subtypes with distinct molecular "fingerprints" that will improve doctors' ability to direct and individualize treatment.

The study, reported online November 22nd in the Journal of Clinical Oncology, is expected to lead to the first use of biomarkers for medulloblastoma in the clinic. The Children's Oncology Group, an international cooperative for childhood cancer research, already plans to apply some of the new data to subtype patients in upcoming clinical trials. Recognition of tumor subtypes will allow patients who need the most aggressive interventions to get them and patients with better prognoses to avoid treatments with potential long-term neurological and cognitive side effects.

"We're basically redefining the disease," says Scott Pomeroy, MD, PhD, Neurologist-in-Chief at Children's and the study's senior author. "This tumor breaks down into subtypes that really act like different diseases, and they will be treated differently looking forward."

The team examined 194 medulloblastomas, accrued through the collaboration of many institutions. "We have far more samples than what was studied before, which gives us much better resolution in determining the number of molecular subtypes represented in medulloblastomas," says first author Yoon-Jae Cho, MD, a neurologist at Children's. "Over the past two decades, Scott has worked very hard to accrue samples here at Children's Hospital and has also created national tumor banks that allow for this type of work to be done."

The study identifies a subtype of medulloblastoma -- never before characterized -- that has the worst prognosis. "We determined the survival rates associated with each molecular subtype," says Cho. "One in particular accounts for a large percentage of tumors that do not respond to current treatments . . . we need to develop more effective strategies to treat this subtype."

Medulloblastomas originate in the cerebellum, a part of the brain that controls motor coordination and other essential functions. The current standard of care is surgery to remove the tumor, followed by a blend of radiation and chemotherapy.

Earlier studies by Pomeroy and others showed that different gene activity patterns in tumor samples correlate with different outcomes -- a better or worse prognosis. The new study went further by examining the DNA of tumors in each category, to see if the differences in gene activity were accompanied by differences in the actual genetic makeup of the subtypes. The researchers examined changes in the number of DNA copies (known as copy number variation) throughout the entire genome of each tumor subtype, and found distinctly different patterns.

"The basic genetic makeup is fundamentally different from one tumor subtype to the next," says Pomeroy.

For example, copies of MYC, a well-known oncogene, are markedly increased in the tumor subtype with the worst prognosis, but not in the other subtypes. In upcoming clinical trials coordinated by the Children's Oncology Group, DNA samples from medulloblastomas will be accessed for the number of MYC copies, and this information will incorporated into treatment decisions. This will mark the first use of biomarkers for medulloblastoma in the clinic.

The team also looked at about 500 microRNAs, regulatory molecules that usually dampen the activity of their target genes. Again, the results revealed distinctly different patterns of microRNA activity across the different medulloblastoma subtypes.

The biomarkers identified in the new findings could potentially be used to personalize treatment by determining the disease subtype and providing information about prognosis within a subtype. A companion study, not yet published, details a model for predicting medulloblastoma relapse that significantly outperforms existing models by integrating disease subtype, other clues gleaned from the genomic analysis and clinical presentation. The model was a collaborative project with the Broad Institute of MIT and Harvard.

"Certain markers portend good outcome in one subtype, but that same marker would be a bad marker in a different subtype . . . this emphasizes the advantage of knowing the molecular subtype of medulloblastoma that you are dealing with," explains Cho.

"Until recently, all we could do is look at brain tumors under the microscope and say what they look like. And knowing what part of the brain they come from, we could say, that looks like medulloblastoma," Pomeroy says. "Now we actually have precise molecular signatures and we know what subtype of medulloblastoma it is. And we can say something about that subtype . . . and what seems to be driving their growth and what the prognosis might be."

These studies were funded by the National Institutes of Health.


Story Source:

The above story is based on materials provided by Children's Hospital Boston. Note: Materials may be edited for content and length.


Journal Reference:

  1. Yoon-Jae Cho, Aviad Tsherniak, Pablo Tamayo, Sandro Santagata, Azra Ligon, Heidi Greulich, Rameen Berhoukim, Vladimir Amani, Liliana Goumnerova, Charles G. Eberhart, Ching C. Lau, James M. Olson, Richard J. Gilbertson, Amar Gajjar, Olivier Delattre, Marcel Kool, Keith Ligon, Matthew Meyerson, Jill P. Mesirov, and Scott L. Pomeroy. Integrative Genomic Analysis of Medulloblastoma Identifies a Molecular Subgroup That Drives Poor Clinical Outcome. Journal of Clinical Oncology, November 22, 2010 DOI: 10.1200/JCO.2010.28.5148

Cite This Page:

Children's Hospital Boston. "Divide and conquer strategy for childhood brain cancer." ScienceDaily. ScienceDaily, 23 November 2010. <www.sciencedaily.com/releases/2010/11/101122172014.htm>.
Children's Hospital Boston. (2010, November 23). Divide and conquer strategy for childhood brain cancer. ScienceDaily. Retrieved August 1, 2014 from www.sciencedaily.com/releases/2010/11/101122172014.htm
Children's Hospital Boston. "Divide and conquer strategy for childhood brain cancer." ScienceDaily. www.sciencedaily.com/releases/2010/11/101122172014.htm (accessed August 1, 2014).

Share This




More Health & Medicine News

Friday, August 1, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

House Republicans Vote to Sue Obama Over Healthcare Law

House Republicans Vote to Sue Obama Over Healthcare Law

Reuters - US Online Video (July 31, 2014) The Republican-led House of Representatives votes to sue President Obama, accusing him of overstepping his executive authority in making changes to the Affordable Care Act. Mana Rabiee reports. Video provided by Reuters
Powered by NewsLook.com
Despite Health Questions, E-Cigs Are Beneficial: Study

Despite Health Questions, E-Cigs Are Beneficial: Study

Newsy (July 31, 2014) Citing 81 previous studies, new research out of London suggests the benefits of smoking e-cigarettes instead of regular ones outweighs the risks. Video provided by Newsy
Powered by NewsLook.com
Dangerous Bacteria Kills One in Florida

Dangerous Bacteria Kills One in Florida

AP (July 31, 2014) Sarasota County, Florida health officials have issued a warning against eating raw oysters and exposing open wounds to coastal and inland waters after a dangerous bacteria killed one person and made another sick. (July 31) Video provided by AP
Powered by NewsLook.com
Health Insurers' Profits Slide

Health Insurers' Profits Slide

Reuters - Business Video Online (July 30, 2014) Obamacare-related costs were said to be behind the profit plunge at Wellpoint and Humana, but Wellpoint sees the new exchanges boosting its earnings for the full year. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins